Markets

Tuesday 4/7 Insider Buying Report: KPTI, OVAS

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

At Karyopharm Therapeutics ( KPTI ), a filing with the SEC revealed that on Thursday, Director Barry E. Greene purchased 3,000 shares of KPTI, at a cost of $29.31 each, for a total investment of $87,938. Greene was up about 13.5% on the buy at the high point of today's trading session, with KPTI trading as high as $33.28 at last check today. Karyopharm Therapeutics is trading up about 10.9% on the day Tuesday. This buy marks the first one filed by Greene in the past year.

And also on Thursday, Chief Executive Officer Michelle Dipp bought $32,490 worth of OvaScience ( OVAS ), buying 1,000 shares at a cost of $32.49 each. Before this latest buy, Dipp purchased OVAS at 4 other times during the past year, for a total cost of $18,614 at an average of $11.28 per share. OvaScience is trading up about 2.9% on the day Tuesday. Dipp was up about 8.3% on the purchase at the high point of today's trading session, with OVAS trading as high as $35.20 in trading on Tuesday.

VIDEO: Tuesday 4/7 Insider Buying Report: KPTI, OVAS

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

KPTI

Other Topics

Investing

Latest Markets Videos

    BNK Invest

    BNK Invest Inc. provides investment services and information. BNK Invest owns and operates a market news family of websites including DividendChannel, ETFChannel, StockOptionsChannel, and others, which make up an investor community featuring stock message boards, ratings, research, and strategies. BNK Invest caters to investing firms and individual investors internationally.

    Learn More